MRFAP1L1: A promising drug target and biomarker for cancer (G114932)

Target Name: MRFAP1L1

NCBI ID: G114932

MRFAP1L1

Other Name(s): MORF4 family-associated protein 1-like 1 | PP784 | MR1L1_HUMAN | Morf4 family associated protein 1 like 1

MRFAP1L1: A promising drug target and biomarker for cancer

Abstract:

Malignant Regulation of Fasting and Eating (MRFAP) is a family of proteins that play a crucial role in the regulation of body weight, metabolism, and inflammation. The MRFAP1L1 protein is a member of the MORF4 family-associated protein 1-like 1 (MRFAP1L1) family, and its function in cell biology is highly conserved with that of its human counterpart, p16INK4a. This gene has been implicated in various diseases, including cancer. In this article, we review the current understanding of MRFAP1L1 and its potential as a drug target and biomarker.

Introduction:

Malignant Regulation of Fasting and Eating (MRFAP) is a complex cellular pathway that regulates the interplay between nutrient availability, metabolism, and inflammation. The MRFAP1L1 protein is a member of the MORF4 family-associated protein 1-like 1 (MRFAP1L1) family, which is highly conserved across various species, including humans. In humans, MRFAP1L1 is primarily expressed in the hypothalamus, an area of the brain responsible for regulating body temperature, hunger, and satiety.

MRFAP1L1 functions as a negative regulator of the Mastermind complex, which is responsible for the development and maintenance of cachexia, a condition characterized by muscle wasting, anorexia, and decreased quality of life. The Mastermind complex includes several key components, including p16INK4a, a well-known protein that is involved in the regulation of cell growth, apoptosis, and inflammation. By regulating the activity of Mastermind components, MRFAP1L1 contributes to the maintenance of cellular homeostasis and the development of various diseases, including cancer.

Potential drug targets and biomarkers:

The potential drug targets for MRFAP1L1 are numerous and range from cellular signaling pathways to metabolic and inflammatory processes. One of the most promising targets is the inhibition of Mastermind-associated signaling pathways, which have been implicated in cancer progression.

1. p16INK4a inhibition:

p16INK4a is a key component of the Mastermind complex and is involved in the regulation of cell growth, apoptosis, and inflammation. Its inhibition has been shown to be a potential therapeutic approach for various diseases, including cancer. In addition to its role in the Mastermind complex, p16INK4a has also been implicated in the regulation of cellular adhesion, migration, and invasion. Therefore, inhibition of p16INK4a signaling pathways could be a promising strategy for cancer treatment.

2. Mastermind-associated signaling pathway inhibition:

The Mastermind signaling pathway is involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. Its inhibition could be a potential therapeutic approach for diseases associated with Mastermind signaling, including cancer.

3. Metabolism and energy homeostasis:

MRFAP1L1 is involved in the regulation of metabolism and energy homeostasis. Its expression is highly correlated with the expression of genes involved in glucose and lipid metabolism, such as Insulin-like growth factor 1 (IGF-1), which is a critical regulator of glucose metabolism. Therefore, modulation of insulin sensitivity and glucose metabolism could be a potential therapeutic approach for diseases associated with obesity and related metabolic disorders.

4. Inflammation:

MRFAP1L1 is involved in the regulation of inflammation, including the regulation of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6. Its expression is highly correlated with the expression of genes involved in inflammation, including nuclear factor kappa B (NF

Protein Name: Morf4 Family Associated Protein 1 Like 1

The "MRFAP1L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRFAP1L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets